August 29, 2016 4:02 PM ET

Healthcare Equipment and Supplies

Company Overview of Veracyte, Inc.

Company Overview

Veracyte, Inc. operates as a molecular diagnostics company. It develops and delivers molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company also offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. In addition, it engages in developing the Percepta Bronchial Genomic Classifier, a gene expression test to identify patients with lung nodules who are at low risk of cancer following...

6000 Shoreline Court

Suite 300

South San Francisco, CA 94080

United States

Founded in 2006

192 Employees

Phone:

650-243-6300

Key Executives for Veracyte, Inc.

Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee
Age: 58
Total Annual Compensation: $457.0K
Chief Operating Officer
Age: 47
Total Annual Compensation: $383.0K
Executive Officer
Age: 56
Total Annual Compensation: $321.0K
Compensation as of Fiscal Year 2015.

Veracyte, Inc. Key Developments

Veracyte, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2016; Reiterates Revenue Guidance for the Year 2016

Veracyte, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2016. For the quarter, the company reported revenue of $14,675,000, loss from operations of $10,494,000, net loss and comprehensive loss of $11,243,000 or $0.40 per basic and diluted share compared to the revenue of $11,908,000, loss from operations of $9,074,000, net loss and comprehensive loss of $9,136,000 or $0.35 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported revenue of $28,225,000, loss from operations of $20,245,000, net loss and comprehensive loss of $21,318,000 or $0.77 per basic and diluted share compared to the revenue of $23,126,000, loss from operations of $16,627,000, net loss and comprehensive loss of $16,746,000 or $0.69 per basic and diluted share for the same period a year ago. The company reiterated its 2016 annual revenue guidance of $59 million to $63 million.

Veracyte, Inc. to Report Q2, 2016 Results on Aug 03, 2016

Veracyte, Inc. announced that they will report Q2, 2016 results at 4:30 PM, US Eastern Standard Time on Aug 03, 2016

Veracyte, Inc., Q2 2016 Earnings Call, Aug 03, 2016

Veracyte, Inc., Q2 2016 Earnings Call, Aug 03, 2016

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 25, 2016
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Veracyte, Inc., please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.